Share This Page
Drugs in ATC Class N07BB
✉ Email this page to a colleague
Drugs in ATC Class: N07BB - Drugs used in alcohol dependence
| Tradename | Generic Name |
|---|---|
| ANTABUSE | disulfiram |
| DISULFIRAM | disulfiram |
| ACAMPROSATE CALCIUM | acamprosate calcium |
| CAMPRAL | acamprosate calcium |
| CONTRAVE | bupropion hydrochloride; naltrexone hydrochloride |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class N07BB (Drugs Used in Alcohol Dependence)
Last updated: July 26, 2026
The ATC N07BB market is concentrated in a small set of active ingredients with differing exclusivity and patent profiles: naltrexone (oral and injectable), acamprosate, disulfiram (including combination products), and nalmefene. Patent estates are the primary driver of generic timing risk, with formulation and long-acting delivery (notably extended-release naltrexone) creating the longest tail into late patent life. The largest near-to-mid-term commercialization pressure typically comes from generics and “authorized” versions in acamprosate and oral naltrexone, while injectable products face steeper IP barriers and longer regulatory/label-relevant design constraints.
How big is the alcohol dependence (ATC N07BB) market and what drives pricing and demand?
Which N07BB molecules generate most revenue
ATC N07BB includes alcohol dependence treatments commonly used across major markets:
- Acamprosate (often oral, multiple brands depending on country)
- Naltrexone (oral; long-acting injectable in some jurisdictions)
- Nalmefene (oral)
- Disulfiram (oral; in some markets as combinations or different tablet strengths)
Market dynamics are driven by:
- Standard-of-care shift toward relapse prevention pharmacotherapy paired with psychosocial support
- Uptake constraints from adherence (oral vs long-acting injections)
- Payor controls and national reimbursement policy
- Safety and tolerability profiles that affect switching between agents
What payors and prescribers optimize
- Reduction of relapse frequency and heavy drinking episodes
- Adherence and clinic workflow fit (especially for injectable naltrexone)
- Liver safety monitoring needs (relevant for naltrexone and disulfiram)
- Contraindications such as current opioid use (naltrexone) and hepatic/psych risk factors (disulfiram)
How generic entry changes N07BB pricing
- Acamprosate and oral naltrexone generally face earlier and faster genericization in many markets once primary and formulation patents expire.
- Long-acting injectable naltrexone has structurally higher IP and manufacturing complexity, slowing entry or pushing design-arounds.
- Nalmefene timelines depend heavily on jurisdiction-specific approvals and patent tail.
What are the exclusivity timelines for N07BB drugs in major markets?
What determines exclusivity in alcohol dependence products
Exclusivity depends on:
- Patent expiration (compound, polymorph/crystal form, salt, formulation, and device/injectable depot systems)
- Regulatory exclusivity where applicable (data protection, marketing exclusivity, orphan exclusivity if relevant)
- Patent term adjustments and patent linkage in the US (Orange Book) affecting Paragraph IV strategies
Timeline snapshot by active ingredient (high-level)
Exact dates vary by country and product version, but the pattern is consistent:
- Acamprosate: typically earlier entry window for generics due to older origin timelines; residual tail often comes from formulation or specific polymorph claims.
- Oral naltrexone: compound patent set often older; stronger barriers are usually formulation/controlled-release or specific dose-form claims in particular jurisdictions.
- Long-acting injectable naltrexone (extended release): later entry due to depot-formulation and manufacturing-process claims.
- Nalmefene: entry timing often governed by jurisdiction-specific patent estates and formulation claims.
- Disulfiram: generally genericized across most markets; tail risk comes from specific strengths, dosing regimens, and formulation IP.
Which patents protect naltrexone for alcohol dependence (oral and extended-release)?
What the patent estate tends to cover
For alcohol dependence use, naltrexone products typically have patent coverage across:
- Active ingredient claims (naltrexone or specific salts)
- Pharmaceutical compositions (instant-release vs controlled release)
- Extended-release depot systems (microspheres, polymer matrices, suspension stabilization)
- Manufacturing methods (particle formation, sterilization, viscosity and rheology control)
- Method-of-use (reduction of heavy drinking, relapse prevention language depending on jurisdiction)
Naltrexone injectable: where generic entry is blocked
Long-acting injectable naltrexone barriers usually cluster around:
- Depot formulation composition (polymer type, drug loading, stabilizers)
- Particle size distribution and morphology
- Process controls to achieve release kinetics
- Device-adjacent constraints (prefilled syringe/container configuration in some jurisdictions)
Naltrexone oral: where generic entry is easiest
Oral naltrexone barriers often narrow to:
- Specific formulation claims for controlled release (if present)
- Polymorph/crystal form claims
- Certain excipient system claims that affect dissolution
Which patents protect acamprosate for alcohol dependence and how many are typically in-force?
What the patent estate tends to cover
Acamprosate coverage commonly includes:
- Composition claims for acamprosate (often with defined salt/structure)
- Formulation claims (tablet coatings, excipient systems)
- Sometimes polymorph/crystal form claims depending on the product history in each jurisdiction
How many patents usually matter for generic timing
For acamprosate, “generic timing risk” is usually not compound-only. The key is whether:
- Later-filed patents exist on specific tablet formulations, coating technologies, or stability-enhancing compositions.
- Local product-specific patents are listed in the relevant regulatory system for that jurisdiction.
Which patents protect nalmefene for alcohol dependence?
Where patent tail risk exists
Nalmefene barriers often come from:
- Formulation patents (release profile)
- Salt/form claims
- Method-of-use claims that are label-relevant in certain jurisdictions
- Manufacturing process controls that support bioavailability stability
Generic entry profile
Generic entry usually depends on whether regulatory equivalents can achieve:
- Bioequivalence with the origin formulation
- Compatible impurity profiles and stability specifications
- Label-specific dosing regimen match (where regulators require tight alignment)
Which patents protect disulfiram for alcohol dependence and what is the generic risk profile?
How the patent landscape typically looks
Disulfiram is broadly genericized in many markets. Residual patent impact tends to be:
- Product-formulation patents (specific excipient system, coating)
- Specific strength combinations if any exist
- Label or method-of-use claims where jurisdictions allow new claims around dosing timing strategies
Where litigation historically concentrates
When disputes occur, they concentrate on:
- Whether generic product formulations infringe specific composition claims
- Whether dosage form and manufacturing process equivalence qualifies for non-infringement
- Whether the origin’s claims are valid over prior art in that jurisdiction
What is the Orange Book status of N07BB drugs and which patents are Orange Book-listed?
US linkage mechanics for alcohol dependence
In the US, Orange Book listing matters because it enables:
- Patent certifications (Paragraph IV, I, II, III, IV depending on status)
- Hatch-Waxman litigation leverage
- Settlement-driven “carve-out” launch dates for generic applicants
US reality for most N07BB products
N07BB listings typically split into:
- Older compound patents already expired
- A smaller number of formulation or method-of-use patents still listed at any point in time
- Injectable products sometimes retain later-listed depot formulation patents
Actionable screening approach (US)
- Identify the reference listed drug (RLD) for each N07BB molecule
- Extract Orange Book “expiration” and “patent number” entries
- Map litigation risk to patents with “patent life” remaining and those tied to formulations that the generic must replicate
How strong is the patent estate for each N07BB molecule (and where are the weak points)?
Strength drivers
Patent estate strength generally increases when the origin controls:
- Depot or controlled-release formulation IP with enforceable composition/process claims
- Label-relevant method-of-use language that survives validity challenges
- Multiple claim categories across product lifecycle (compound, polymorph, composition, method, manufacturing)
Relative strength by molecule (typical pattern)
- Long-acting injectable naltrexone: typically strongest estate due to depot systems and process claims that require specific implementation choices.
- Oral naltrexone and acamprosate: medium to low residual risk depending on jurisdiction; often reduced by generic availability and older origin filings.
- Nalmefene: medium risk tied to formulation and local patent tail.
- Disulfiram: low residual risk in most markets due to broad generic availability; local exceptions can occur if newer formulation patents exist.
Which companies hold the key N07BB product approvals and patent rights?
Common origin holder pattern
The market tends to split among:
- Innovator companies that develop and maintain depot injectable formulations
- Generic incumbents that hold authorized generics or locally registered versions
- Specialty pharma companies that commercialize nalmefene and disulfiram variants depending on region
How to use company mapping for licensing and litigation
For business planning:
- Prioritize origin holders that maintain US Orange Book listings for each product strength and dosage form.
- Identify whether the origin is litigating or licensing proactively in the category.
- Track whether challengers file Paragraph IV certifications against specific patents (composition vs method-of-use vs process).
What patent litigation affects N07BB drugs, including Paragraph IV challenges and settlements?
How N07BB litigation typically unfolds
For US products with Orange Book listings:
- Generic files an ANDA with patent certifications against listed patents
- If Paragraph IV is filed, origin typically sues within statutory timelines
- Cases can settle with launch date provisions and stipulations
Where the highest probability of dispute exists
- Depot injectable naltrexone formulation patents (composition/process)
- Last remaining method-of-use patents tied to alcohol dependence relapse prevention claims
Commercial impact of settlements
Settlements usually:
- Fix entry dates for specific generic dosage strengths
- Impose design constraints in the generic label or formulation
- Bind future applicants through platform knowledge (process parameter targets)
How do formulation patents for alcohol dependence drugs affect generic manufacturing and bioequivalence?
What formulation patents cover
Formulation patents for N07BB often protect:
- Drug loading and release kinetics
- Polymer selection and ratio
- Stabilizer and surfactant systems
- Particle size and distribution
- Viscosity and suspension stability
- Sterility assurance processes compatible with depot systems
Bioequivalence constraints
Even if a generic clears bioequivalence requirements, infringement can hinge on:
- Composition structure equivalents (not just plasma curves)
- Manufacturing route differences that still produce infringing particle attributes
- Timing and sampling endpoints in BE studies that may not map to product performance language in claims
What generic entry risks exist for N07BB drugs by dosage form (oral vs injectable)?
Oral products
Key entry risks:
- Formulation patents tied to controlled release or stability
- Salt/polymorph claims (if any remain in-force)
- Process claims that affect impurity profiles
Injectables
Key entry risks:
- Composition and process claims for the depot formulation
- Container closure system claims in certain jurisdictions
- Sterile manufacturing and aseptic fill-finish process claims
Regulatory path alignment
- ANDA applicants for generics must match reference listed drug dosage form and route.
- For depot injectables, the generic must match release characteristics sufficiently while avoiding infringement.
How does acamprosate compare with naltrexone in market access and patent survivability?
Commercial positioning
- Acamprosate is often viewed as relapse prevention with dosing schedules that are easy to prescribe but adherence dependent.
- Naltrexone is used both for heavy drinking reduction strategies and relapse prevention, with extended-release injectable versions used to reduce adherence friction.
Patent survivability comparison
- Acamprosate patent estates typically thin earlier due to older origin filings and broad generic adoption in many territories.
- Injectable naltrexone typically has longer patent tail due to formulation complexity and process-specific claims.
How does nalmefene compare with disulfiram in patent barriers and generic availability?
- Nalmefene’s generic risk is typically tied to formulation and method-of-use claims that may vary by jurisdiction.
- Disulfiram tends to have lower residual patent barriers due to widespread generic availability; where barriers remain, they usually relate to newer formulations, specific strengths, or updated dosing regimens.
What are the regulatory milestones and how do they interact with patent expiry for N07BB products?
US milestones
- ANDA submission timing relative to patent expiry
- Patent certification type and litigation timeline
- 180-day exclusivity triggers for first filers (if applicable)
EU/other markets
- National patent enforcement can diverge from regulatory approval timelines
- Data protection and local marketing authorizations influence entry scheduling beyond patent dates alone
Key Takeaways
- N07BB alcohol dependence therapy IP is concentrated in formulation and method-of-use patents, with long-acting injectable naltrexone typically carrying the longest and strongest patent tail.
- Oral products such as acamprosate and oral naltrexone often face faster genericization where compound and earlier formulation patents have already expired; residual risk is mostly formulation-specific and jurisdiction-specific.
- Patent linkage systems such as the US Orange Book meaningfully shape generic entry through Paragraph IV leverage and settlement-driven launch scheduling.
- The practical generic entry barrier differs by dosage form: oral generics face narrower formulation/process claim sets; injectables face depot composition and process claim clusters that are harder to design around.
FAQs
- How do method-of-use patents for alcohol dependence affect generic label approval for N07BB drugs?
- Which N07BB patents most commonly trigger Paragraph IV ANDA challenges in the US?
- What formulation changes can create non-infringement risk for long-acting injectable naltrexone generics?
- How does data protection timing in the EU interact with patent expiry for acamprosate and naltrexone?
- Do settlements in alcohol dependence generics typically set fixed launch dates or impose formulation limitations?
References (APA)
- European Medicines Agency (EMA). (n.d.). ATC classification and product information for alcohol dependence medicines (ATC N07BB). European Medicines Agency.
- FDA. (n.d.). Drugs@FDA database and Orange Book drug product and patent listings for naltrexone, acamprosate, nalmefene, and disulfiram products. U.S. Food and Drug Administration.
- European patent and litigation databases. (n.d.). Public patent register and litigation outcomes for N07BB-related active ingredients and formulations.
More… ↓
